G Biasco

Summary

Affiliation: University of Bologna
Country: Italy

Publications

  1. ncbi request reprint Treatment of liver metastases from colorectal cancer: what is the best approach today?
    G Biasco
    Institute of Hematology and Medical Oncology L e A Seràgnoli, University of Bologna, S Orsola Malpighi Hospital, Italy
    Dig Liver Dis 33:438-44. 2001
  2. ncbi request reprint Cancer surveillance in ulcerative colitis: critical analysis of long-term prospective programme
    G Biasco
    Institute of Haematology and Oncology, L e A Seràgnoli and Interdipartimental Centre for Cancer Research G Prodi, University of Bologna, Italy
    Dig Liver Dis 34:339-42. 2002
  3. ncbi request reprint Folate and prevention of colorectal cancer in ulcerative colitis
    G Biasco
    Universita di Bologna, Istituto di Ematologia e Oncologia Medica L e A Seragnoli, Policlinico S Orsola Malpighi, Via Massarenti, 9, 40138 Bologna, Italy
    Eur J Cancer Prev 14:395-8. 2005
  4. ncbi request reprint Treatment of hepatic metastases from colorectal cancer: many doubts, some certainties
    G Biasco
    L and A Seràgnoli Institute of Haematology and Medical Oncology, S Orsola Malpighi Hospital, University of Bologna, Bologna, Italy
    Cancer Treat Rev 32:214-28. 2006
  5. ncbi request reprint Impact of surgery on the development of duodenal cancer in patients with familial adenomatous polyposis
    G Biasco
    Institute of Haemathology and Medical Oncology L and A Seràgnoli, Via Massarenti 9, 40138, Bologna, Italy
    Dis Colon Rectum 49:1860-6. 2006
  6. ncbi request reprint European trials on dietary supplementation for cancer prevention
    G Biasco
    Istituto di Ematologia ed Oncologia Medica Ludovico e Ariosto Seràgnoli, University of Bologna, Italy
    Ann N Y Acad Sci 889:152-6. 1999
  7. ncbi request reprint Chemoprevention of colorectal cancer
    G Biasco
    Seragnoli Institute, University of Bologna, Bologna, Italy
    Int J Biol Markers 18:75-7. 2003
  8. doi request reprint Surgical debulking of gastrointestinal stromal tumors: is it a reasonable option after second-line treatment with sunitinib?
    M A Pantaleo
    Institute of Hematology and Medical Oncology L A Seragnoli, Sant Orsola Malpighi Hospital, University of Bologna, Via Massarenti 9, 40126 Bologna, Italy
    J Cancer Res Clin Oncol 134:625-30. 2008
  9. doi request reprint Experimental results and related clinical implications of PET detection of epidermal growth factor receptor (EGFr) in cancer
    M A Pantaleo
    Institute of Hematology and Medical Oncology L A Seragnoli, Sant Orsola Malpighi Hospital, University of Bologna, Via Massarenti 9, 40138 Bologna, Italy
    Ann Oncol 20:213-26. 2009
  10. ncbi request reprint Molecular imaging and targeted therapies in oncology: new concepts in treatment response assessment. a collection of cases
    M A Pantaleo
    University of Bologna, Institute of Hematology and Medical Oncology L and A Seragnoli, Sant Orsola Malpighi Hospital, I 40138 Bologna, Italy
    Int J Oncol 33:443-52. 2008

Collaborators

Detail Information

Publications50

  1. ncbi request reprint Treatment of liver metastases from colorectal cancer: what is the best approach today?
    G Biasco
    Institute of Hematology and Medical Oncology L e A Seràgnoli, University of Bologna, S Orsola Malpighi Hospital, Italy
    Dig Liver Dis 33:438-44. 2001
    ..Combined hepatic artery and systemic treatment may provide a new strategy as adjuvant therapy for patients undergoing resections...
  2. ncbi request reprint Cancer surveillance in ulcerative colitis: critical analysis of long-term prospective programme
    G Biasco
    Institute of Haematology and Oncology, L e A Seràgnoli and Interdipartimental Centre for Cancer Research G Prodi, University of Bologna, Italy
    Dig Liver Dis 34:339-42. 2002
    ..Patients with longstanding ulcerative colitis are at increased risk of colorectal cancer. In the literature, no agreement has yet been reached regarding prevention strategies. Our report sums up a prospective study started in 1980...
  3. ncbi request reprint Folate and prevention of colorectal cancer in ulcerative colitis
    G Biasco
    Universita di Bologna, Istituto di Ematologia e Oncologia Medica L e A Seragnoli, Policlinico S Orsola Malpighi, Via Massarenti, 9, 40138 Bologna, Italy
    Eur J Cancer Prev 14:395-8. 2005
    ..Folate maintains the normal DNA methylation process and steady-state levels of DNA precursors. These properties indicate that folate has potential as chemopreventive agent...
  4. ncbi request reprint Treatment of hepatic metastases from colorectal cancer: many doubts, some certainties
    G Biasco
    L and A Seràgnoli Institute of Haematology and Medical Oncology, S Orsola Malpighi Hospital, University of Bologna, Bologna, Italy
    Cancer Treat Rev 32:214-28. 2006
    ..In case of relapse, another hepatectomy should be considered. The role of novel targeted therapies in pre-operative, post-operative and palliative management has yet to be evaluated...
  5. ncbi request reprint Impact of surgery on the development of duodenal cancer in patients with familial adenomatous polyposis
    G Biasco
    Institute of Haemathology and Medical Oncology L and A Seràgnoli, Via Massarenti 9, 40138, Bologna, Italy
    Dis Colon Rectum 49:1860-6. 2006
    ..We proposed to determine the frequency, natural history, cumulative risk, and risk factors of the precancerous duodenal lesions in a series of patients diagnosed in northern Italy...
  6. ncbi request reprint European trials on dietary supplementation for cancer prevention
    G Biasco
    Istituto di Ematologia ed Oncologia Medica Ludovico e Ariosto Seràgnoli, University of Bologna, Italy
    Ann N Y Acad Sci 889:152-6. 1999
    ..ECP in collaboration with EURONUT has also started a multinational intervention study of the effect of H. pylori eradication and/or dietary supplementation with vitamin C on intestinal metaplasia...
  7. ncbi request reprint Chemoprevention of colorectal cancer
    G Biasco
    Seragnoli Institute, University of Bologna, Bologna, Italy
    Int J Biol Markers 18:75-7. 2003
  8. doi request reprint Surgical debulking of gastrointestinal stromal tumors: is it a reasonable option after second-line treatment with sunitinib?
    M A Pantaleo
    Institute of Hematology and Medical Oncology L A Seragnoli, Sant Orsola Malpighi Hospital, University of Bologna, Via Massarenti 9, 40126 Bologna, Italy
    J Cancer Res Clin Oncol 134:625-30. 2008
    ..Most patients have an unresectable disease and do not have any other therapeutical options except for clinical trials...
  9. doi request reprint Experimental results and related clinical implications of PET detection of epidermal growth factor receptor (EGFr) in cancer
    M A Pantaleo
    Institute of Hematology and Medical Oncology L A Seragnoli, Sant Orsola Malpighi Hospital, University of Bologna, Via Massarenti 9, 40138 Bologna, Italy
    Ann Oncol 20:213-26. 2009
    ..As a consequence, various critical questions are still open, and the implications of a translation in the clinical setting for EGFr imaging in cancer patients is discussed...
  10. ncbi request reprint Molecular imaging and targeted therapies in oncology: new concepts in treatment response assessment. a collection of cases
    M A Pantaleo
    University of Bologna, Institute of Hematology and Medical Oncology L and A Seragnoli, Sant Orsola Malpighi Hospital, I 40138 Bologna, Italy
    Int J Oncol 33:443-52. 2008
    ....
  11. ncbi request reprint Circadian variations of rectal cell proliferation in patients affected by advanced colorectal cancer
    G Brandi
    Institute of Hematology and Medical Oncology L and A Seragnoli, pad 8, S Orsola Hospital, Via Massarenti 9, 40138 Bologna, Italy
    Cancer Lett 208:193-6. 2004
    ..The study of the rhythmicity of the intestinal cells may be useful to modulate the infusion of antiproliferative agents to prevent damage of the normal colorectal mucosa...
  12. doi request reprint Molecular imaging suggests efficacy of bevacizumab beyond the second line in advanced colorectal cancer patients
    G Brandi
    Institute of Hematology and Medical Oncology L and A Seragnoli, University of Bologna, Bologna, Italy
    Chemotherapy 54:421-4. 2008
    ..Molecular imaging techniques seem to be mandatory in the era of tailored therapy since it is useful to have an in vivo 'biological picture' of the neoplastic disease...
  13. pmc Advances in preclinical therapeutics development using small animal imaging and molecular analyses: the gastrointestinal stromal tumors model
    M A Pantaleo
    Department of Hematology and Oncology Sciences L A Seragnoli, Sant Orsola Malpighi Hospital, University of Bologna, 40138, Bologna, Italy
    Clin Exp Med 9:199-205. 2009
    ..This approach of cancer research on GISTs is crucial and essential for innovative perspectives that could cross over to other types of cancer...
  14. ncbi request reprint The potential role of IGF1r in young adult patients with gastroinetstinal stromal tumor (GIST)
    M Pantaleo
    University of Bologna, Bologna, Italy
    J Clin Oncol 27:10562. 2009
    ..Some interesting results about IGF1r were published on GISTs. However, until now the real role on the pathogenesis of this disease and its clinical implications still needs to be defined...
  15. ncbi request reprint Evaluation of Ki-67 in gastrointestinal stromal tumor (GIST)
    M Saponara
    University of Bologna, Bologna, Italy
    J Clin Oncol 27:e21510. 2009
    ..However, few but controversial data on Ki-67 are also available. The aim of our study was to clarify the role of Ki-67 expression as a new biological marker in GISTs...
  16. ncbi request reprint Integrative analysis of gene expression profiling and high-resolution genomic copy number in gastrointestinal stromal tumor (GIST)
    M Nannini
    University of Bologna, Bologna, Italy
    J Clin Oncol 27:10559. 2009
    ..10559 Background: Besides mutually exclusive cKIT or PDGFRA mutations, sequential accumulation of other genetic events may be involved in GISTs development and progression, but very few data is still available...
  17. ncbi request reprint Microscopic margins of resection in gastrointestinal stromal tumor (GIST): An analysis of 122 patients
    M Di Battista
    University of Bologna, Bologna, Italy
    J Clin Oncol 27:10554. 2009
    ..The prognosis is strongly correlated with both tumor size and mitotic index. The aim of our study was to analyze retrospectively the outcome of patients affected by GIST related to microscopic margins of resection...
  18. ncbi request reprint Gene expression profiling of liver metastases from colorectal cancer: differences between synchronous and metachronous lesions
    M A Pantaleo
    Insitute of Hematology and Medical Oncology, Bologna, Italy Pediatric Oncology and Hematology, Bologna, Italy Insitute of Hematology and Medical Oncology, Bologna, Italy CRBA, Bologna, Italy Liver and Multi organ Transplantation, Bologna, Italy Insitute of Hematology and Medical Oncology, Bologna, Italy
    J Clin Oncol 26:15062. 2008
    ..We studied the gene expression profiling of liver metastases in order to identify some molecular differences for differentiating the systemic therapies in these two clinical setting...
  19. pmc Gene expression profiling of liver metastases from colorectal cancer as potential basis for treatment choice
    M A Pantaleo
    Institute of Hematology and Medical Oncology LA Seragnoli, S Orsola Malpighi Hospital, University of Bologna, Bologna, Italy
    Br J Cancer 99:1729-34. 2008
    ..Synchronous or metachronous liver metastases could be treated differently on the basis of different molecular pathways...
  20. ncbi request reprint Identification of SDHA (subunit A of the succinate dehydrogenase) mutations in KIT/PDGFRA WT gastrointestinal stromal tumors (GISTs)
    M A Pantaleo
    Seragnoli Department and GIST Study Group, University of Bologna, Bologna, Italy Interdepartmental Centre for Cancer Research, Bologna, Italy Giorgio Prodi Cancer Research Center, University of Bologna, Bologna, Italy Interdepartmental Centre of Cancer Research G Prodi, University of Bologna, Bologna, Italy University of Bologna, Bologna, Italy Azienda ULSS 9 Treviso, Treviso, Italy Portland VA Medical Center and Oregon Health and Science University Knight Cancer Institute, Portland, OR Pathology Unit, S Orsola Malpighi Hospital, Bologna, Italy Emergency Surgery and Transplant Department, S Orsola Malpighi Hospital, University of Bologna, Bologna, Italy Pathology, S Orsola Malpighi Hospital, Bologna, Italy Policlinico Sant Orsola Malpighi, Bologna, Italy BC Cancer Agency Genome Sciences Centre, Vancouver, BC, Canada Novartis Oncology, Varese, Italy
    J Clin Oncol 29:10045. 2011
    ..We analyzed the tumor transcriptome of two sporadic young adults WT GISTs patients using massively parallel sequencing approach in order to identify novel genetic mutations...
  21. ncbi request reprint Impact of adjuvant chemotherapy on time to relapse in cholangiocarcinoma
    S Di Girolamo
    University of Bologna, Bologna, Italy S Orsola Malpighi Hospital, Bologna, Italy
    J Clin Oncol 29:299. 2011
    ..In adjuvant setting only few randomized trials using no standard treatments and producing controversial data are reported in literature...
  22. ncbi request reprint [Treatment of colorectal cancer liver metastases]
    E Derenzini
    Istituto di Ematologia e Oncologia Medica L e A Seragnoli, Policlinico S Orsola Malpighi Università di Bologna, Bologna
    Minerva Med 97:107-19. 2006
    ..Probably in the next years new targeted drugs and locoregional therapies will contribute to further improve prognosis of such patients, in a neoadjuvant, adjuvant and palliative setting...
  23. pmc Molecular determination of epidermal growth factor receptor in normal and neoplastic colorectal mucosa
    G Piazzi
    1Centre of Applied Biomedical Research CRBA, S Orsola Malpighi Hospital, University of Bologna, Via Massarenti 9, Bologna 40138, Italy
    Br J Cancer 95:1525-8. 2006
    ..Phosphorylated (pY1068) EGFr detection in CRC may be a better tool than EGFr detection to select patients for targeted therapies...
  24. ncbi request reprint Cell proliferation and ultrastructural changes of the duodenal mucosa of patients affected by familial adenomatous polyposis
    G Biasco
    Istituto di Ematologia ed Oncologia Medica L A Seragnoli, Dipartimento di Medicina Interna e Gastroenterologia, Universita di Bologna, Bologna, Italy
    Hum Pathol 35:622-6. 2004
    ..These abnormalities may be considered as intermediate biomarkers of neoplasia and potential surrogate endpoints in chemoprevention studies...
  25. doi request reprint Molecular detection of epidermal growth factor receptor in colorectal cancer: does it still make sense?
    M Nannini
    Department of Hematology and Oncology Sciences L A Seragnoli, S Orsola Malpighi Hospital, University of Bologna, Bologna, Italy
    Colorectal Dis 13:542-8. 2011
    ....
  26. ncbi request reprint Correlation between endoscopic features of gastric antrum, histology and Helicobacter pylori infection in adults
    C Calabrese
    Department of Internal Medicine and Gastroenterology, University of Bologna, Italy
    Ital J Gastroenterol Hepatol 31:359-65. 1999
    ..The present prospective study has correlated this and other endoscopic features, defined by Sydney classification of gastritis, both to Helicobacter pylori presence and histological patterns...
  27. ncbi request reprint Complete remission of primary colon cancer in a metastatic patient treated with CPT-11 plus capecitabine
    G Brandi
    Institute of Hematology and Medical Oncology L and A Seragnoli, Policlinico Sant Orsola Malpighi, University of Bologna, Via Massarenti 9, 40138 Bologna, Italy
    Int J Colorectal Dis 19:599-602. 2004
    ..The best treatment of patients with advanced colorectal cancer at the time of diagnosis is not well known, and the medical treatment is still unsatisfactory...
  28. ncbi request reprint MicroRNA profile in gastrointestinal stromal tumors (GISTs) and correlation with KIT/PDGFRA kinase genotype
    S Formica
    Interdepartmental Centre of Cancer Research G Prodi, University of Bologna, Bologna, Italy Interdepartmental Centre for Cancer Research, Bologna, Italy University of Bologna, Bologna, Italy Seragnoli Department and GIST Study Group, University of Bologna, Bologna, Italy Dipartimento di Medicina Sperimentale e Diagnostica, University of Ferrara, Ferrara, Italy Pathology Unit, S Orsola Malpighi Hospital, Bologna, Italy L and A Seràgnoli Department of Hematology and Oncological Sciences, Bologna, Italy Emergency Surgery and Transplant Department, S Orsola Malpighi Hospital, University of Bologna, Bologna, Italy Azienda ULSS 9 Treviso, Treviso, Italy
    J Clin Oncol 29:10056. 2011
    ..On the contrary, up to now, really few data are available on microRNAs. We studied the miRNA profiles in GISTs correlated with kinase genotype...
  29. ncbi request reprint Effect of the serine proteases inhibitor gabexate mesylate (GM) on the activity of gemcitabine (G) in cell lines of pancreatic cancer (PC)
    G Brandi
    University of Bologna, S Orsola Malpighi Hospital, Bologna, Italy Centro di Ricerca Biomedica Applicata CRBA, Bologna, Italy University of Bologna, Bologna, Italy Department of Hematology and Oncological Science, Bologna, Italy
    J Clin Oncol 27:e15645. 2009
    ..GM is an inhibitor of u-PA,TAT, trypsin and plasmin, used in Italy and Japan for prophylaxis of acute pancreatitis after ERCP. In a previous study, GM demonstrated antinvasion and antimetastatic activity...
  30. pmc Radiotherapy in the management of gist: state of the art and new potential scenarios
    L Gatto
    Department of Specialized, Experimental, and Diagnostic Medicine, S Orsola Malpighi Hospital, University of Bologna, Bologna, Italy
    Clin Sarcoma Res 7:1. 2017
    ..Historically GIST has been considered radiation-resistant, and the role of radiotherapy in the management of patients with GIST is currently restricted to symptomatic palliation in current treatment guidelines...
  31. pmc Hypersensitivity reactions related to oxaliplatin (OHP)
    G Brandi
    Institute of Haematology and Medical Oncology L and A Seragnoli, University of Bologna, Policlinico Sant Orsola, Via Massarenti 9, 40138 Bologna, Italy
    Br J Cancer 89:477-81. 2003
    ..The cumulative dose, the time of exposure to OHP and the clinical features are variable and unpredictable. The risk of developing hypersensitivity reactions in patients treated with a short infusion of OHP cannot be underestimated...
  32. ncbi request reprint Metronomic capecitabine as second-line treatment for patients with hepatocellular carcinoma with preserved liver function: A phase II study
    F De Rosa
    University of Bologna, Bologna, Italy Azienda Ospedaliera di Bologna, Policlinico S Orsola Malpighi, Bologna, Italy
    J Clin Oncol 29:e14608. 2011
    ..Metronomic chemotherapy is characterized by antiangiogenic activity as well and good tolerability. Therefore we started a phase II clinical study to assess efficacy of metronomic capecitabine in advanced HCC patients...
  33. ncbi request reprint Bone metastases from gastrointestinal stromal tumors (GISTs)
    M Nannini
    University of Bologna, Bologna, Italy L and A Seràgnoli Department of Hematology and Oncological Sciences, Bologna, Italy Department of Radiology, Policlinico Sant Orsola Malpighi Bologna University, Bologna, Italy Seragnoli Department and GIST Study Group, University of Bologna, Bologna, Italy Interdepartmental Centre for Cancer Research, Bologna, Italy Interdepartmental Centre of Cancer Research G Prodi, University of Bologna, Bologna, Italy
    J Clin Oncol 29:e20527. 2011
    ..Bone metastases represent a rare finding in clinical practice and their biological significance and clinical management remain unsettled...
  34. ncbi request reprint Second-line chemotherapy in patients with biliary tract cancer
    G Brandi
    University of Bologna, Bologna, Italy S Orsola Malpighi Hospital, Bologna, Italy
    J Clin Oncol 29:e14590. 2011
    ..Our retrospective study aims at evaluating retrospectively the impact of second-line chemotherapy in this setting...
  35. ncbi request reprint Targeted therapy in colorectal cancer: do we know enough?
    M A Pantaleo
    Institute of Hematology and Medical Oncology L A Seragnoli, University of Bologna, Sant Orsola Malpighi Hospital, Via Massarenti 9, Bologna 40138, Italy
    Dig Liver Dis 38:71-7. 2006
    ..Moreover, the efficacy does not show any correlation with the molecular expressions of the tumours. In this review, we considered different hypotheses in order to explain these results...
  36. ncbi request reprint Targeted therapies in solid tumours: results and promises
    M A Pantaleo
    L and A Seragnoli, Institute of Medical Hematology and Oncology, S Orsola Malpighi Polyclinic, Bologna, Italy
    Minerva Med 98:603-23. 2007
    ..A selection of patients who could have beneficial effects from the novel agents is mandatory to avoid inappropriate therapies and also unjustified expenses...
  37. ncbi request reprint Mutagenic and clastogenic activity of gastric juice in human gastric diseases
    P Hrelia
    Dipartimento di Farmacologia, Universita degli Studi di Bologna, Via Irnerio 48, 40126, Bologna, Italy
    Mutat Res 514:125-32. 2002
    ..13 versus 0.38+/-0.51; P<0.001). These findings expand our knowledge of gastric disease risk factors, and indicate that there may well be a risk of mucosal DNA damage arising from the presence of mutagenic and CF in the gastric juice...
  38. ncbi request reprint Identification of single nucleotide variants in gastrointestinal stromal tumor KIT/PDGFRA wild-type (WT GISTs) by massively parallel sequencing
    V Indio
    Giorgio Prodi Cancer Research Center, University of Bologna, Bologna, Italy Seragnoli Department and GIST Study Group, University of Bologna, Bologna, Italy Interdepartmental Centre for Cancer Research, Bologna, Italy University of Bologna, Bologna, Italy Interdepartmental Centre of Cancer Research G Prodi, University of Bologna, Bologna, Italy BC Cancer Agency Genome Sciences Centre, Vancouver, BC, Canada Emergency Surgery and Transplant Department, S Orsola Malpighi Hospital, University of Bologna, Bologna, Italy Pathology Unit, S Orsola Malpighi Hospital, Bologna, Italy Portland VA Medical Center and Oregon Health and Science University Knight Cancer Institute, Portland, OR Novartis Oncology, Varese, Italy Azienda ULSS 9 Treviso, Treviso, Italy
    J Clin Oncol 29:10046. 2011
    ..However the causative genomic alterations of these GISTs still remain unknown. Massively parallel sequencing allows identifying novel putative variants...
  39. doi request reprint Port-a-Cath-related complications in 252 patients with solid tissue tumours and the first report of heparin-induced delayed hypersensitivity after Port-a-Cath heparinisation
    I Garajova
    L and A Seragnoli Department of Hematology and Oncological Sciences, University of Bologna, Bologna, Italy
    Eur J Cancer Care (Engl) 22:125-32. 2013
    ..We are first to describe heparin-induced delayed hypersensitivity after heparinisation of Port-a-Cath. This fact should influence the preference to keep the Port-a-Cath after completion of adjuvant anticancer treatment...
  40. ncbi request reprint Conventional and novel PET tracers for imaging in oncology in the era of molecular therapy
    M A Pantaleo
    Institute of Hematology and Medical Oncology L and A Seragnoli, Sant Orsola Malpighi Hospital, University of Bologna, Bologna, Italy
    Cancer Treat Rev 34:103-21. 2008
    ..The aim of this review is to analyze the current role of conventional and innovative positron emission tomography (PET) radiotracers in clinical practice and to explore the promising perspectives of molecular imaging in cancer research...
  41. ncbi request reprint Cold single-strand conformation polymorphism analysis: optimization for detection of APC gene mutations in patients with familial adenomatous polyposis
    P Strippoli
    Institute of Histology and Embryology, University of Bologna, I-40138 Bologna, Italy
    Int J Mol Med 8:567-72. 2001
    ..This modified cold-SSCP method provides a simple and effective way for detecting several known Apc gene mutations without any loss of sensitivity and could be useful for large-scale molecular diagnosis of FAP...
  42. ncbi request reprint Pantoprazole, azithromycin and tinidazole: short duration triple therapy for eradication of Helicobacter pylori infection
    C Calabrese
    Department of Internal Medicine and Gastroenterology, University of Bologna, Italy
    Aliment Pharmacol Ther 14:1613-7. 2000
    ..Azithromycin is an acid-stable macrolide that achieves remarkably high concentrations in gastric tissue, persisting above the MIC90 for Helicobacter pylori over a period of 5-days, after a single 500 mg oral dose...
  43. ncbi request reprint Bacteria in biopsies of human hypochlorhydric stomach: a scanning electron microscopy study
    G Brandi
    Istituto di Clinica Medica e Gastroenterologia, Policlinico S Orsola, Bologna, Italy
    Ultrastruct Pathol 20:203-9. 1996
    ..In such areas, mechanical and biochemical damage may occur...
  44. ncbi request reprint Concurrent EGFr and Cox-2 expression in colorectal cancer: proliferation impact and tumour spreading
    C Ceccarelli
    Centre of Applied Biomedical Research CRBA, S Orsola Malpighi Hospital, University of Bologna, Italy
    Ann Oncol 16:iv74-79. 2005
    ..At least three molecular pathways (EGFr, Cox-2, and APC/beta-catenin molecular cascade) may interact in this malignancy giving rise to cross talking effects on proliferation and cancer spreading...
  45. ncbi request reprint Helicobacter pylori infection and gastric function in patients with fundic atrophic gastritis
    A Tucci
    Department of Internal Medicine and Gastroenterology, Hospital S. Orsola-Malpighi, University of Bologna, Italy
    Dig Dis Sci 46:1573-83. 2001
    ..Our data suggest that fundic atrophic gastritis represents a possible end stage of H. pylori infection, characterized by a progressive disappearance of the bacterium and a progressive deterioration of gastric functions...
  46. ncbi request reprint Cancer of the appendix in long-standing ulcerative colitis: a case report
    U Zannoni
    Istituto di Ematologia e Oncologia Medica L. e A. Seragnoli, Bologna, Italy
    Tumori 83:958-9. 1997
    ..These findings suggest that appendiceal cancer and UC may be unrelated diseases. A surveillance program for early detection of cancer of the appendix in patients with long-standing UC does not seem mandatory...
  47. ncbi request reprint Slow evolution of liver metastasis from colon cancer
    G Biasco
    Dig Liver Dis 37:628-9. 2005
  48. ncbi request reprint PET detection of epidermal growth factor receptor in colorectal cancer: a real predictor of response to cetuximab treatment?
    M A Pantaleo
    Eur J Nucl Med Mol Imaging 34:1510-1. 2007
  49. ncbi request reprint The role of cetuximab in pre-treated refractory patients with metastatic colorectal cancer: outcome study in clinical practice
    G Lelli
    Oncology Units of S Anna Hospital, Ferrara, Italy
    J Chemother 20:374-9. 2008
    ..0001, p<0.0001, p=0.006). According to multivariate analysis, the absence of weight loss was related to longer TTP (HR 0.331, p=0.004) and OS (HR 0.176, p<0.0001), and EGFR over-expression (3+) to longer TTP (HR 0.402, p=0.020)...
  50. pmc Risk of duodenal cancer in patients with familial adenomatous polyposis
    G Biasco
    Gut 53:1547; author reply 1547. 2004